Disseminated Coinfection by Mycobacterium fortuitum and Talaromyces marneffei in a Non-HIV Case

References

• ZhuangB, WuC, LinG. [Resistance of Mycobacterium fortuitum against varied physical factors and its survival in different surroundings]. Zhonghua Jie He He Hu Xi Za Zhi. 2001;24(11):679–681. Chinese.16136908
   PubMedGoogle Scholar
• OkamoriS, AsakuraT, NishimuraT, et al. Natural history of Mycobacterium fortuitum pulmonary infection presenting with migratory infiltrates: a case report with microbiological analysis. BMC Infect Dis. 2018;18(1):1. doi:10.1186/s12879-017-2892-929291713
   PubMed Web of Science ®Google Scholar
• CortiM, SotoI, VillafañeF, EsquivelP, Di LonardoM. [Disseminated infection due to Mycobacterium fortuitum in an AIDS patient]. Medicina (B Aires). 1999;59(3):274–276. Spanish.10451568
   PubMed Web of Science ®Google Scholar
• ToK, CaoR, YegiazaryanA, OwensJ, VenketaramanV. General Overview of Nontuberculous Mycobacteria Opportunistic Pathogens: mycobacterium avium and Mycobacterium abscessus. J Clin Med. 2020;9(8):2541. doi:10.3390/jcm9082541
   PubMed Web of Science ®Google Scholar
• ShamaeiM, MirsaeidiM. Nontuberculous Mycobacteria, Macrophages, and Host Innate Immune Response. Infect Immun. 2021;89(8):e0081220. doi:10.1128/IAI.00812-2034097459
   PubMed Web of Science ®Google Scholar
• EarlyJ, FischerK, BermudezLE. Mycobacterium avium uses apoptotic macrophages as tools for spreading. Microb Pathog. 2011;50(2):132–139. doi:10.1016/j.micpath.2010.12.00421167273
   PubMed Web of Science ®Google Scholar
• TomiokaH, TatanoY, MawWW, SanoC, KanehiroY, ShimizuT. Characteristics of suppressor macrophages induced by mycobacterial and protozoal infections in relation to alternatively activated M2 macrophages. Clin Dev Immunol. 2012;2012:635451. doi:10.1155/2012/63545122666284
   PubMedGoogle Scholar
• ThiriotJD, Martinez-MartinezYB, EndsleyJJ, TorresAG. Hacking the host: exploitation of macrophage polarization by intracellular bacterial pathogens. Pathog Dis. 2020;78(1):ftaa009. doi:10.1093/femspd/ftaa00932068828
   PubMed Web of Science ®Google Scholar
• JohansenMD, KremerL. CFTR Depletion Confers Hypersusceptibility to Mycobacterium fortuitum in a Zebrafish Model. Front Cell Infect Microbiol. 2020;10:357. doi:10.3389/fcimb.2020.0035732850470
   PubMed Web of Science ®Google Scholar
• LuS, HuY, LuC, ZhangJ, LiX, XiL. Development of in vitro macrophage system to evaluate phagocytosis and intracellular fate of Penicillium marneffei conidia. Mycopathologia. 2013;176(1–2):11–22. doi:10.1007/s11046-013-9650-323645133
   PubMed Web of Science ®Google Scholar
• PongpomM, VanittanakomP, NimmaneeP, CooperCRJr, VanittanakomN. Adaptation to macrophage killing by Talaromyces marneffei. Future Sci OA. 2017;3(3):FSO215. doi:10.4155/fsoa-2017-003228884011
   PubMed Web of Science ®Google Scholar
• LuS, LiD, XiL, CalderoneR. Interplay of interferon-gamma and macrophage polarization during Talaromyces marneffei infection. Microb Pathog. 2019;134:103594. doi:10.1016/j.micpath.2019.10359431199985
   PubMed Web of Science ®Google Scholar
• DuanH, HanX, WangQ, et al. Clinical Significance of Nontuberculous Mycobacteria Isolated From Respiratory Specimens in a Chinese Tuberculosis Tertiary Care Center. Sci Rep. 2016;6(1):36299. doi:10.1038/srep3629927808247
   PubMed Web of Science ®Google Scholar
• ParkS, SuhGY, ChungMP, et al. Clinical significance of Mycobacterium fortuitum isolated from respiratory specimens. Respir Med. 2008;102(3):437–442. doi:10.1016/j.rmed.2007.10.00517997087
   PubMed Web of Science ®Google Scholar
• HirabayashiR, NakagawaA, TakegawaH, TomiiK. A case of pleural effusion caused by Mycobacterium fortuitum and Mycobacterium mageritense coinfection. BMC Infect Dis. 2019;19(1):720. doi:10.1186/s12879-019-4366-831416441
   PubMed Web of Science ®Google Scholar
• Soto-ArquíñigoL, García-ParejaM, Gotuzzo-HerenciaE, Legua-LeivaP, Sánchez-HerreraM. [Co-infection by Mycobacterium fortuitum and Mycobacterium tuberculosis in splenic abscesses in a patient with HIV]. Rev Peru Med Exp Salud Publica. 2017;34(2):328–331. doi:10.17843/rpmesp.2017.342.2470. Catalan.29177396
   PubMedGoogle Scholar
• Su-S-S, ZhangS-N, YeJ-R, et al. <p>Disseminated Talaromyces marneffei And Mycobacterium avium Infection Accompanied Sweet’s Syndrome In A Patient With Anti-Interferon-γ Autoantibodies: a Case Report. Infect Drug Resist. 2019;12:3189–3195. doi:10.2147/IDR.S21883631632104
   PubMed Web of Science ®Google Scholar
• XuH, LiuD, HeX, ZhengD, DengY. Sweet’s Syndrome Associated with Talaromyces marneffei and Mycobacterium abscessus Infection Due to Anti-interferon-gamma Autoantibodies. Indian J Dermatol. 2018;63(5):428–430. doi:10.4103/ijd.IJD_362_1730210169
   PubMed Web of Science ®Google Scholar
• PruetpongpunN, KhawcharoenpornT, DamronglerdP, et al. Disseminated Talaromyces marneffei and Mycobacterium abscessus in a Patient With Anti-Interferon-γ Autoantibodies. Open Forum Infect Dis. 2016;3(2):ofw093. doi:10.1093/ofid/ofw09327419165
   PubMed Web of Science ®Google Scholar
• SeokH, KoJH, ShinI, et al. Disseminated Talaromyces marneffei and Mycobacterium intracellulare coinfection in an HIV-infected patient. Int J Infect Dis. 2015;38:86–88. doi:10.1016/j.ijid.2015.07.02026232630
   PubMed Web of Science ®Google Scholar
• ZhangJ, HuangX, ZhangX, et al. Coinfection of disseminated Talaromyces marneffei and Mycobacteria kansasii in a patient with papillary thyroid cancer: a case report. Medicine (Baltimore). 2017;96(52):e9072. doi:10.1097/MD.000000000000907229384899
   PubMed Web of Science ®Google Scholar
• DingX, HuangH, ZhongL, et al. Disseminated Talaromyces marneffei Infection in a Non-HIV Infant With a Homozygous Private Variant of RELB. Front Cell Infect Microbiol. 2021;11:605589. doi:10.3389/fcimb.2021.60558933791233
   PubMed Web of Science ®Google Scholar
• ChetchotisakdP, KiertiburanakulS, MootsikapunP, AssanasenS, ChaiwarithR, AnunnatsiriS. Disseminated nontuberculous mycobacterial infection in patients who are not infected with HIV in Thailand. Clin Infect Dis. 2007;45(4):421–427. doi:10.1086/52003017638188
   PubMed Web of Science ®Google Scholar
• SantosPE, PiontelliE, SheaYR, et al. Penicillium piceum infection: diagnosis and successful treatment in chronic granulomatous disease. Med Mycol. 2006;44(8):749–753. doi:10.1080/1369378060096708917127632
   PubMed Web of Science ®Google Scholar
• DavidsonPT. The other mycobacteria. Chest. 1979;75(2):110–111. doi:10.1378/chest.75.2.110421541
   PubMed Web of Science ®Google Scholar
• HienH, ThanhTT, ThuN, et al. Development and evaluation of a real-time polymerase chain reaction assay for the rapid detection of Talaromyces marneffei MP1 gene in human plasma. Mycoses. 2016;59(12):773–780. doi:10.1111/myc.1253027453379
   PubMed Web of Science ®Google Scholar
• ChirasuthatP, TriyangkulsriK, RutninS, ChanprapaphK, VachiramonV. Cutaneous nontuberculous mycobacterial infection in Thailand: a 7-year retrospective review. Medicine (Baltimore). 2020;99(10):e19355. doi:10.1097/MD.000000000001935532150075
   PubMed Web of Science ®Google Scholar
• UngpakornR. Cutaneous manifestations of Penicillium marneffei infection. Curr Opin Infect Dis. 2000;13(2):129–134. doi:10.1097/00001432-200004000-0000611964779
   PubMed Web of Science ®Google Scholar
• LeeWJ, KangSM, SungH, et al. Non-tuberculous mycobacterial infections of the skin: a retrospective study of 29 cases. J Dermatol. 2010;37(11):965–972. doi:10.1111/j.1346-8138.2010.00960.x21039785
   PubMed Web of Science ®Google Scholar
• KothavadeRJ, DhuratRS, MishraSN, KothavadeUR. Clinical and laboratory aspects of the diagnosis and management of cutaneous and subcutaneous infections caused by rapidly growing mycobacteria. Eur J Clin Microbiol Infect Dis. 2013;32(2):161–188. doi:10.1007/s10096-012-1766-823139042
   PubMed Web of Science ®Google Scholar
• NashKA, ZhangY, Brown-ElliottBA, WallaceRJJr. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J Antimicrob Chemother. 2005;55(2):170–177. doi:10.1093/jac/dkh52315590712
   PubMed Web of Science ®Google Scholar
• DaleyCL, IaccarinoJM, LangeC, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: an Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline: executive Summary. Clin Infect Dis. 2020;71(4):e1–e36. doi:10.1093/cid/ciaa24132628747
   PubMed Web of Science ®Google Scholar
• ShenY, WangX, JinJ, et al. In Vitro Susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum Isolates to 30 Antibiotics. Biomed Res Int. 2018;2018:4902941. doi:10.1155/2018/490294130687747
   PubMed Web of Science ®Google Scholar